These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9490924)

  • 21. A pilot study of the effects of gonadotropin-releasing hormone agonist therapy on brain activation pattern in a man with pedophilia.
    Moulier V; Fonteille V; Pélégrini-Issac M; Cordier B; Baron-Laforêt S; Boriasse E; Durand E; Stoléru S
    Int J Offender Ther Comp Criminol; 2012 Feb; 56(1):50-60. PubMed ID: 21518701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hormonal therapy in metastatic prostatic cancer].
    Ruffion A; Fontaine E; Staerman F
    Prog Urol; 2003 Apr; 13(2):334-41. PubMed ID: 12765081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H; Kanetake H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hormone level regulation – less traumatic than castration].
    Arborelius UP
    Lakartidningen; 2016 Aug; 113():. PubMed ID: 27505853
    [No Abstract]   [Full Text] [Related]  

  • 26. Chemical castration for sex offenders.
    Grubin D; Beech A
    BMJ; 2010 Jan; 340():c74. PubMed ID: 20068060
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of advanced prostate cancer: can we improve on androgen deprivation therapy?
    Anderson J; Abrahamsson PA; Crawford D; Miller K; Tombal B
    BJU Int; 2008 Jun; 101(12):1497-501. PubMed ID: 18336613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controversies in the management of advanced prostate cancer.
    Tyrrell CJ
    Br J Cancer; 1999 Jan; 79(1):146-55. PubMed ID: 10408706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormonal ablation therapy for metastatic prostatic carcinoma: a review.
    Leewansangtong S; Soontrapa S
    J Med Assoc Thai; 1999 Feb; 82(2):192-205. PubMed ID: 10087729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The fate of the medically castrated testis: expectation versus reality.
    Issa MM; Krishnan A; Bouet R; Young MR; Hood N; Petros JA
    J Urol; 2004 Sep; 172(3):1042-4. PubMed ID: 15311033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug treatment of prostatic carcinoma].
    Witjes JA; Debruyne FM
    Ned Tijdschr Geneeskd; 1997 Sep; 141(39):1855-8. PubMed ID: 9545743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Criminal recidivism among sexual offenders].
    Bengtson S; Lund J
    Ugeskr Laeger; 2008 Dec; 170(49):4035-9. PubMed ID: 19087745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Operative castration in sexual delinquency--a survey of topical literature and an attempt at forming an opinion].
    Rossner M
    Psychiatr Neurol Med Psychol (Leipz); 1979 Jun; 31(6):321-8. PubMed ID: 396539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medroxyprogesterone acetate antiandrogen treatment of hypersexuality in a pedophiliac sex offender.
    Cordoba OA; Chapel JL
    Am J Psychiatry; 1983 Aug; 140(8):1036-9. PubMed ID: 6223535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "Chemical castration" for sex offenders.
    Berlin FS
    N Engl J Med; 1997 Apr; 336(14):1030. PubMed ID: 9091797
    [No Abstract]   [Full Text] [Related]  

  • 36. Indonesian doctors risk losing licence if they castrate paedophiles.
    Parry J
    BMJ; 2016 Oct; 355():i5762. PubMed ID: 27780813
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment and resocialization of sexual delinquents by anti-androgen and psychotherapy].
    Jost F
    Schweiz Arch Neurol Neurochir Psychiatr; 1979; 124(2):243-53. PubMed ID: 493886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Luteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength.
    Williams MB; Hernandez J; Thompson I
    J Urol; 2005 Apr; 173(4):1067-71. PubMed ID: 15758703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.